Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP)

ConclusionDupilumab, omalizumab, and mepolizumab are approved for patients 18  years of age and older with CRSwNP as add-on therapy to intranasal corticosteroids when, for dupilumab and mepolizumab, therapy with systemic corticosteroids and/or surgery does not achieve sufficient disease control. Therapy with omalizumab is indicated when therapy with intranasal corticosteroid s does not result in sufficient disease control. Dedicated recommendations for the documentation of the use in the German health care system are given, which are based on the position papers of our author group already published on this topic.
Source: Allergo Journal International - Category: Allergy & Immunology Source Type: research